The aim of the partnership is to develop new diagnostic biomarkers and therapies for pancreatic cancer, according to a statement from NCKU.
The partnership calls for the establishment of a satellite laboratory at the cancer center of NCKU’s hospital in Tainan, Taiwan.
Last year, Ohio State University Medical Center led a phase 2 pancreatic cancer trial of a drug developed by Oncolytics Biotech.
“Pancreatic cancer is typically diagnosed at a later stage, where there is a poor prognosis for long-term survival,” said the study’s principal investigator. “Although the standard of care has evolved over the last few years, it has only managed to generate very modest improvements in response rate and median overall survival at best.”